Substituted pyridinone-pyridinyl compounds

摘要

The present disclosure provides pyridinone-pyridinyl compounds useful in the treatment of p38 kinase mediated diseases, such as lymphoma and auto-inflammatory disease, having the structure of Formula (I):;
wherein R1, R2, R3, R4, R5, X and Y are as defined in the detailed description; pharmaceutical compositions comprising at least one of the compounds; and methods for treating p38 kinase mediated diseases using the compound.

主权项

1. A compound having the structure of Formula (I):or a pharmaceutically acceptable salt thereof, wherein:
X and Y are independently selected from the group consisting of CH and N, with the proviso that when X is CH, Y is N, and when X is N, Y is CH; R1 is selected from the group consisting of C1-C6-alkyl, halo and —H; R2 is selected from the group consisting of alkyl and alkoxy; wherein the alkyl or alkoxy is optionally substituted with one or more heterocyclyl which is optionally substituted with one or more substituents independently selected from the group consisting of alkyl, alkoxy and cyano; R3 and R4 are independently selected from the group consisting of alkyl, halo and —H; and R5 is selected from the group consisting of cycloalkyl, aryl, and heterocyclyl; wherein the cycloalkyl or aryl is optionally substituted with one or more substituents independently selected from the group consisting of halo, cyano, alkyl, hydroxyalkyl, alkoxyalkyl and aminoalkyl; and wherein the heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of cyano, alkyl, hydroxyalkyl, alkoxyalkyl and aminoalkyl.